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The bacterial second messenger cyclic diguanylate (c-di-GMP) reg-
ulates a wide range of cellular functions from biofilm formation to
growth and survival. Targeting a second-messenger network is
challenging because the system involves a multitude of compo-
nents with often overlapping functions. Here, we present a strat-
egy to intercept c-di-GMP signaling pathways by directly targeting
the second messenger. For this, we developed a c-di-GMP–
sequestering peptide (CSP) that was derived from a CheY-like
c-di-GMP effector protein. CSP binds c-di-GMP with submicromolar
affinity. The elucidation of the CSP·c-di-GMP complex structure by
NMR identified a linear c-di-GMP–binding motif, in which a self-
intercalated c-di-GMP dimer is tightly bound by a network of H
bonds and π-stacking interactions involving arginine and aromatic
residues. Structure-based mutagenesis yielded a variant with con-
siderably higher, low-nanomolar affinity, which subsequently was
shortened to 19 residues with almost uncompromised affinity. We
demonstrate that endogenously expressed CSP intercepts c-di-
GMP signaling and effectively inhibits biofilm formation in Pseu-
domonas aeruginosa, the most widely used model for serious
biofilm-associated medical implications.
c-di-GMP | biofilm | peptide design | protein dynamics |
NMR solution structure
Bacterial second messengers are small signaling moleculesthat regulate a myriad of intracellular processes in response
to extracellular stimuli or primary internal cues. For example,
cyclic adenosine monophosphate (cAMP) controls carbon me-
tabolism (1), (p)ppGpp has been linked to the stringent response
and to nutrient stress (2), cyclic diguanylate (c-di-GMP) regu-
lates motility, cell-cycle progression, biofilm formation, and vir-
ulence (3), cyclic GMP-AMP (3′3′-cGAMP) participates in host
colonization (4) and antiphage protection (5), and cyclic ade-
nylate (c-di-AMP) controls potassium homeostasis (6). Because
second messengers act as master regulators for a wide range of
important biological processes in bacteria, they are attractive
drug targets to control bacterial infections. C-di-GMP signaling
is widespread in gram-positive and gram-negative bacteria, in-
cluding many medically important pathogens associated with
multidrug resistance such as Pseudomonas aeruginosa, Escherichia
coli, Klebsiella pneumoniae, or Clostridium difficile (7). Impor-
tantly, c-di-GMP is a central regulator of biofilms, multicellular
bacterial communities that are engulfed in a self-produced ma-
trix (3, 8). In the human host, pathogens often form biofilms that
confer tolerance to antibiotics and host immunity, rendering
classical treatment options ineffective (9). This includes chronic
infections of airways of cystic fibrosis patients, urinary tract in-
fections, and endocarditis, as well as colonization of medical
implants and catheters (10). Despite the obvious medical rele-
vance of biofilms, effective antibiofilm strategies are scarce and
drugs for the specific treatment of biofilms have not been
approved so far.
Interfering with c-di-GMP signaling has been proposed as a
promising strategy to treat biofilm-related diseases (11, 12). C-di-
GMP is synthesized and degraded by diguanylate cyclases
(DGCs) and phosphodiesterases (PDEs), respectively. Increased
production of c-di-GMP promotes the transition from a motile,
single-cell state to a sessile lifestyle, where flagella are inacti-
vated (13), adhesins are expressed (14), and exopolysaccharide
biosynthesis is induced (15), leading to biofilm formation. In
contrast, a targeted reduction of c-di-GMP prevents biofilm
formation and eradicates existing biofilms (16). Consequently,
specific inhibition of DGCs or activation of PDEs have been
regarded as the most promising approaches to control biofilms
(reviewed in refs. 17 and 18). However, bacteria often harbor
multiple copies of genes encoding c-di-GMP catalysts. For in-
stance, P. aeruginosa encodes 17 different proteins with a DGC
domain (GGDEF), five proteins with a PDE domain (EAL or
HD-GYP), and 16 proteins containing both domains (GGDE-
F-EAL hybrids) (17). This diversity and redundancy of c-di-GMP
turnover enzymes may represent a major challenge in the de-
velopment of small molecules that globally interfere with c-di-
GMP signaling pathways (18). This challenge is exacerbated by
recent research showing that c-di-GMP levels are not globally
regulated; some DGCs and PDEs affect local concentration,
while others contribute to the overall concentration (19).
Therefore, despite common catalytic mechanisms, it will be very
challenging to develop highly specific and nontoxic compounds
with broad effectiveness against multiple enzymes. As a universal
solution to overcome this hurdle it has been proposed to directly
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target the c-di-GMP molecule. Sintim and coworkers have pio-
neered this approach and identified several small molecules that
lead to the aggregation of c-di-GMP in bacterial cells (20). Al-
though the inhibitory effects of these small molecules are moderate,
it is encouraging that c-di-GMP signaling can be manipulated by
directly targeting the common product (c-di-GMP) of these
enzymes.
We have recently shown that a short arginine-rich region lo-
cated at the C termini of a novel family of CheY-like (Cle)
proteins in Caulobacter crescentus binds c-di-GMP with nano-
molar affinity (21). Grafting of a stretch of 36 amino acids from
the C terminus of CleD onto the E. coli CheY protein or onto a
SUMO carrier protein conveyed high c-di-GMP affinity. This
indicated that the c-di-GMP binding site is fully contained within
these short C-terminal peptides and prompted us to test if they
could be used as c-di-GMP–sequestering peptides (CSPs). Here,
we demonstrate that the C-terminal peptide from CleD is suf-
ficient to bind c-di-GMP with nanomolar affinity, a binding af-
finity higher than most of the known c-di-GMP effectors (22). To
reveal the structural basis for this high affinity, we determined
the NMR structure and dynamics of this CSP·c-di-GMP com-
plex. The results revealed a c-di-GMP–binding motif in which
two intercalated ligand molecules are embraced by the peptide
and form numerous H-bonding and cation–π interactions with
arginines and stacking interactions with two tyrosine rings. An in-
depth structure–activity analysis confirmed the importance of
these structural motifs and allowed the development of a minimal,
high-affinity CSP. Overexpression of such a CSP in P. aeruginosa
reduced free intracellular c-di-GMP and effectively inhibited
biofilm formation. These data show the potential of short peptides
with high ligand-binding affinity to effectively sequester small
signaling molecules like c-di-GMP. This opens the possibility to
interfere with second messenger-based signaling networks in
bacteria without the need to provide for specific chemical inhibi-
tors of large families of catalysts.
Results
A Short Peptide Is Sufficient to Bind C-di-GMP with High Affinity. To
obtain detailed insights into the binding mechanism of c-di-GMP
to CSPs, we expressed and purified a peptide corresponding to
the conserved arginine-rich C-terminal region of CleD (amino
acids 140 to 174) using a standard E. coli system (see Materials
and Methods for details). Isothermal calorimetry (ITC) experi-
ments showed that this peptide, designated CSP1 (Table 1),
binds c-di-GMP with a dissociation constant (Kd) of 108 nM and
a stoichiometry of two c-di-GMP molecules per one CSP peptide
(SI Appendix, Fig. S1A). Thus, both affinity and stoichiometry of
c-di-GMP binding to CSP1 are almost identical to full-length
CleD (Kd = 86 nM) (21), indicating that the short stretch of
amino acids fully retains all determinants to specifically bind
c-di-GMP with high affinity. This observation is remarkable since
in all other known protein complexes, c-di-GMP binding involves
amino acids from more than one protein region (23).
The Structure of the CSP·c-di-GMP Complex Reveals a Hitherto
Unknown Binding Motif. Next, we analyzed the interaction be-
tween CSP1 and c-di-GMP by NMR. The amino acids of apo
CSP1 show 1H-15N resonances in the central, random coil region
of the HSQC (heteronuclear single quantum coherence) spec-
trum (Fig. 1A), which are indicative of an unfolded protein. In
contrast, the addition of c-di-GMP to CSP1 induces large
chemical shift changes toward a well-dispersed spectrum, giving
evidence that the peptide has undergone a transition to a folded
structure. The 13Cα, 13Cβ, and 13C′ secondary chemical shifts
(Fig. 1B) of complexed CSP1 indicate a mixed secondary structure,
with residues E143 to E146 and V151 to P153 in β-strands and
residues R169 to D172 in a helical-turn conformation, respectively.
Interestingly, despite its unfolded character, apo CSP1 retains about
30% propensity for the β-strands in residues E143 to E146 and V151
to P153 but no propensity for the helical turn (Fig. 1B).
CSP1 binding to c-di-GMP induces the appearance of four
imino 1H resonances in the region between 11 and 14 ppm (parts
per million), which are indicative of the H-bonded imino groups
in the intercalated c-di-GMP dimer (Fig. 1D) (24). Identical
imino 1H resonances were observed in the complex of c-di-GMP
with full-length CleD. A comparison of the imino regions of the
NOESY (nuclear Overhauser effect spectroscopy) spectra from
these two complexes (Fig. 1E) shows identical contacts of these
imino protons to the coordinating amino acids. Therefore, the
CSP1 peptide binds to c-di-GMP in an identical way as to the
entire CleD protein.
A well-defined three-dimensional (3D) solution structure of
the CSP1·c-di-GMP complex was determined based on a total of
732 NOEs comprising 465 intrapeptide, 86 intra–c-di-GMP, and
181 intermolecular NOEs as well as 52 residual dipolar cou-
plings, yielding a heavy-atom rmsd of 0.2 Å in the ordered region
of the peptide backbone (SI Appendix, Table S4). The structure
(Figs. 2 C and D and 3A) reveals that the peptide is wrapped
around the self-intercalated c-di-GMP dimer with a small
N-terminal β-hairpin (V145 to G152), providing a hydrophobic
platform (V145, Y150) for interaction with Gua1, one of the
peripheral guanine residues. Residue D154 forms a bifurcated H
bond between one of its side-chain oxygens with Gua1-N1 and
the main-chain amide of residue R156. This is followed by R155
and R156 that form lateral H bonds with the Hoogsteen edges of
Gua1 and Gua3, respectively. Y163 stacks onto the other pe-
ripheral Gua4 and is part of a loop, which leads to R169 and
D172 interacting with Gua2 and Gua4, respectively. In-
terestingly, the backbone of this segment is folded to a helical
turn defined by the R169-O···D172-N H bond. Exactly the same
arrangement occurs for the intercalated c-di-GMP bound to the
RxxD motif of the functionally and structurally unrelated
diguanylate cyclase PleD (Fig. 3 A and B). Apparently, this turn
conformation of the main chain in CSP1 is required to properly
position the side chains of R169 and D172 for H bonding with
the dimeric ligand. Of note, all interacting arginines align lat-
erally with the guanine bases, whereas in other dimeric c-di-
GMP–protein complexes also head-on interactions (involving
the terminal side-chain amino groups) are observed. Further-
more, the irregular conformation of the peptide allows also two
main-chain groups to engage in ligand H bonding (R155-NH···
Gua1-O6, K168-NH···Gua4-O6).
Besides the aforementioned H bonds, the guanidinium groups
of R155, R156, and R169 form the common cation–π interac-
tions with Gua3, Gua1, and Gua4, described in other c-di-
GMP–binding proteins (25). In addition, R155 stacks with Y150
from the β-hairpin. Conspicuously, the Hoogsteen edge of Gua4
is not occupied but is in close proximity to the side chain of
K168. An arginine at this position would be ideally suited to
interact with the Gua4 Hoogsteen edge in a manner similar to
the other three arginine–guanine pairs. Indeed, most Cle paral-
ogs have an arginine at this position (Fig. 2B) and a K168R
mutation of CSP1 (CSP2) increased the affinity fivefold (Kd =
19 nM; Table 1 and SI Appendix, Fig. S1B).
In summary, most of the ligand-binding functionality of CSP1
can be attributed to two conserved sequence motifs (DRR and
[R/K]RxxD; Fig. 2B), which are separated by only 11 residues.
This is distinct from other c-di-GMP–binding proteins where li-
gand binding invariably involves several discontinuous sequence
regions separated by many amino acids. Furthermore, the CSP1
structure suggests that the c-di-GMP binding site of CleD (21) is
completely defined by this relatively short domain.
Structure–Activity Relationship Defines the Minimal Requirement for
C-di-GMP Binding. To obtain insights into the role of individual
amino acids in the stabilization of the CSP1·c-di-GMP complex,
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we investigated its dynamics by 15N relaxation experiments (SI
Appendix, Fig. S2). The Lipari–Szabo order parameter S2 (26)
derived from these data is shown in Fig. 2E. S2 values around 0.9
for D154, R155, R156, and R169, which are involved in H bonds
to the ligand, and for A171, at the C terminus, are indicative of a
well-defined structure with only small-amplitude motions of the
N-H vector on the nanosecond timescale. In contrast, residues at
the N and C termini, of the loop ranging from R157 to K168, and
most residues of the β-hairpin have S2 values smaller than 0.8,
indicative of large nanosecond motions. Further motions in the
micro- to millisecond time range are observable by chemical
exchange broadening (Rex) of the
15N transverse relaxation
rates for residues located in the N-terminal β-hairpin (Fig. 2E;
V145, A147, A149, Y150, G152). Apparently, the β-hairpin is
unstable on this timescale. The observed nano- to millisecond
motions in the different regions of the CSP1·c-di-GMP complex
also coincide with a low definition of the respective local structure
(Fig. 2C).
As the β-hairpin is dynamic and only few of its residues are in
van der Waals contact with the rest of the structure, we hy-
pothesized that this part of the peptide may not be relevant for
ligand binding. In order to identify the shortest CSP derivative
that maintains high c-di-GMP–binding affinity, we generated
several shorter CSP variants (Table 1). Since the K168R mutant
peptide confers higher affinity to c-di-GMP than wild-type CSP1,
this mutation was included in the peptide design of all sub-
sequent variants. Omitting the flexible N- and C-terminal resi-
dues (variant CSP3, residues W144 to D172) reduced the affinity
about eightfold (Kd = 154 nM). We then removed the entire
N-terminal β-hairpin and reduced the peptide to the 19 amino
acids DRRRFNSADYKGPRRRKAD (D154 to D172, variant
CSP4). Remarkably, this drastic pruning reduced the affinity
only moderately (Kd = 177 nM), in agreement with the observed
dynamical instability of the N-terminal β-hairpin. Shorter vari-
ants (CSP5 to CSP8) bound the ligand very weakly or not at all
(Table 1). Likewise, single amino acid deletions in the partially
flexible loop from R157 to G165 resulted in significantly higher
Kd values (CSP28 to CSP34; Table 1 and SI Appendix, Fig. S2B).
Thus, CSP4 is the shortest CSP variant that retains high affinity
to c-di-GMP.
Next, we performed single amino acid substitutions in CSP4 to
characterize their role in c-di-GMP binding. All residues were
replaced individually by alanine except for A161 and A171,
which were replaced by leucine. The c-di-GMP affinities of these
variants (CSP9 to CSP27) were measured by ITC and the results
are summarized in Table 1 and Fig. 2F. Mutations of residues
Table 1. CSP derivatives and their affinities to c-di-GMP
CSP Sequence Amino acids Kd, nM
140 150 160 170
01234567890123456789012345678901234
1* SKPREWVEAVAYVGPDRRRFNSADYKGPRKRKADAS 36 108
2* SKPREWVEAVAYVGPDRRRFNSADYKGPRRRKADAS 36 19
3 WVEAVAYVGPDRRRFNSADYKGPRRRKAD 29 154
4† DRRRFNSADYKGPRRRKAD 19 177
5 RRRFNSADYKGPRRR 15 No binding
6 RRRFNSADYKGPRRRKAD 18 1,406
7 DRRRFNSADYKGPRRRK 17 1,709
8 DRRRFNSADYKGPRRR 16 No binding
9 ARRRFNSADYKGPRRRKAD 19 1,754
10 DARRFNSADYKGPRRRKAD 19 1,468
11 DRARFNSADYKGPRRRKAD 19 1,512
12 DRRAFNSADYKGPRRRKAD 19 782
13 DRRRANSADYKGPRRRKAD 19 140
14 DRRRFASADYKGPRRRKAD 19 221
15 DRRRFNAADYKGPRRRKAD 19 209
16 DRRRFNSLDYKGPRRRKAD 19 102
17 DRRRFNSAAYKGPRRRKAD 19 145
18 DRRRFNSADAKGPRRRKAD 19 4,365
19 DRRRFNSADYAGPRRRKAD 19 261
20 DRRRFNSADYKAPRRRKAD 19 7,657
21 DRRRFNSADYKGARRRKAD 19 346
22 DRRRFNSADYKGPARRKAD 19 1,835
23 DRRRFNSADYKGPRARKAD 19 4,798
24 DRRRFNSADYKGPRRAKAD 19 No binding
25 DRRRFNSADYKGPRRRAAD 19 273
26 DRRRFNSADYKGPRRRKLD 19 251
27 DRRRFNSADYKGPRRRKAA 19 1,719
28 DRR-FNSADYKGPRRRKAD 18 1,038
29 DRRR-NSADYKGPRRRKAD 18 1,271
30 DRRRF-SADYKGPRRRKAD 18 1,253
31 DRRRFN-ADYKGPRRRKAD 18 439
32 DRRRFNS-DYKGPRRRKAD 18 338
33 DRRRFNSA-YKGPRRRKAD 18 437
34 DRRRFNSADYK-PRRRKAD 18 1,948
Sequence variations compared with CSP1 are indicated with bold letters.
*Produced using a recombinant method.
†CSP4 and CSP9 to CSP34 are acetylated at the N terminus and amidated at the C terminus.
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that interact directly with c-di-GMP (D154, R155, R156, Y163,
R168, R169, D172) significantly reduced the c-di-GMP–binding
affinity. Strong reductions in binding also occurred for mutations
of R157, G165, and R167, which are not in direct contact with
the ligand in the NMR structure. G165 has a positive phi angle,
disallowed for all other residue types, which is required for the
backbone turn at this position (Fig. 2D). The side chains of R157
and R167 were not well-defined in the structure and these ar-
ginines may participate in further undetected interactions with
the ligand. The replacement of all other residues that are not
directly involved in c-di-GMP binding had little effect on c-di-
GMP affinity. Thus, the effects of single amino acid substitutions
on c-di-GMP binding agree perfectly with the NMR structural
and dynamical data.
CSP Binds C-di-GMP with High Specificity.While some effector proteins
that bind cyclic dinucleotide second messengers (CDNs) show high
ligand specificity, others like the endoplasmic reticulum-resident
protein STING can bind several CDNs (27–31). To test if CSP
binds c-di-GMP specifically, we used microscale thermophoresis.
Binding of c-di-GMP to CSP4 was compared with related nucle-
otides including GMP, GTP (guanosine triphosphate), pGpG, and
four naturally occurring CDNs (3′3′-c-di-GMP, 3′3′-c-di-AMP, 3′
3′-cGAMP, and 2′3′-cGAMP). As shown in SI Appendix, Fig. S3,
only c-di-GMP binding to CSP4 was observed, while none of the
related nucleotides or CDNs was able to bind to the peptide.
From this, we concluded that CSP binds c-di-GMP with high af-
finity and specificity. This can be explained by the base-specific
H-bonding interactions of Gua1 to Gua4 via their Hoogsteen edge
to the guanidinium groups of the peptide arginines.
Expression of CSP Inhibits P. aeruginosa Biofilm Formation by
Sequestering C-di-GMP. To test if CSP is able to sequester free
c-di-GMP and by this inhibit biofilm formation, plasmids were
constructed to express peptides from an IPTG (isopropyl β-D-1-
thiogalactopyranoside)-inducible promoter (for details, see Materials
and Methods). When CSP4 was expressed in P. aeruginosa, the
peptide could not be detected by mass spectrometry and no
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Fig. 1. Ligand binding and induced folding of CSP1. (A) 1H-15N HSQC spectra of apo CSP1 (green) and the CSP1·c-di-GMP complex (blue). Resonances are
marked with assignment information. The arginine side-chain protons He, Hη1, and Hη2 are in exchange with water in the apo form and are not observed.
Their appearance in the complex spectrum indicates their engagement in hydrogen bonds. Resonances in red are aliased in the 15N dimension and belong to
the complex. (B) Secondary 13Cα, 13C′, 13Cβ, and 15N chemical shifts of apo (green) and complex CSP1 (blue). Secondary structure elements of the CSP1·c-di-GMP
complex are shown (Top) and highlighted in blue in the amino acid sequence of CSP1. (C) Chemical structure of c-di-GMP. (D) Structure of the intercalated
c-di-GMP dimer as determined in the complex with CSP1. (E) Evidence for identical dimeric c-di-GMP structure and coordination in the complexes with CSP1
and full-length CleD. (E, Left) Extracted region of the 2D NOESY spectrum of the c-di-GMP·CSP1 complex showing the NOE contacts of the four imino protons
H1 of guanines 1 to 4. The large numbers of c-di-GMP to peptide and c-di-GMP to c-di-GMP contacts define the ligand coordination. (E, Right) Identical region
of the NOESY spectrum of the c-di-GMP·CleD complex. Identical imino proton chemical shifts and NOE contacts of the ligand dimer are observed as for the
c-di-GMP·CSP1 complex.
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effect on biofilm formation was observed. Since it is well-known
that short peptides are highly susceptible to proteolytic degra-
dation (32), CSP4 was fused to Venus fluorescent protein for
stability and detection. Although Venus–CSP4 expression was
detected by monitoring fluorescence, the expression did not in-
terfere with biofilm formation. We reckoned that the affinity of
Venus–CSP4 might not be high enough to sequester c-di-GMP
and subsequently tested CSP2, which is the variant with highest
affinity. CSP2 was fused to maltose-binding protein (MBP) to
improve stability and to a hexahistidine (H6) tag for detection
(Fig. 4A). The purified H6-MBP–CSP2 fusion protein showed a
Kd of 124.7 nM (SI Appendix, Fig. S1C), a value that is about
sixfold higher than the Kd measured for CSP2 alone (SI Ap-
pendix, Fig. S1B). Thus, the hexahistidine and MBP tags seem to
partially interfere with c-di-GMP binding of CSP2. Importantly,
the purified H6-MBP–CSP2-R169A control protein showed no
binding of c-di-GMP (SI Appendix, Fig. S1D). In agreement with
its ability to bind c-di-GMP in vitro, expression of H6-MBP–
CSP2 effectively inhibited P. aeruginosa biofilm formation in a
concentration-dependent manner. In contrast, expression of the
H6-MBP–CSP2-R169Amutant peptide, unable to bind c-di-GMP,
had no effect on biofilm formation (Fig. 4 B and C). When biofilm
formation was scored over time, strains expressing the two
constructs showed a similar increase during the first 8 h, before
the accumulation of surface-associated biomass was blocked
abruptly upon expression of the CSP2 fusion, while steadily in-
creasing in the mutant control (Fig. 4D). This indicated that ex-
pression of H6-MBP–CSP2, although unable to inhibit initial
surface attachment of P. aeruginosa cells, was very effective in
suppressing the process at later stages of biofilm formation. When
peptide fusions were expressed in preformed biofilms, the c-di-
GMP–specific effect, although smaller, could still be observed
(Fig. 4E). Finally, we tested if H6-MBP–CSP2 expression was able
to reduce antibiotic-induced biofilm formation in P. aeruginosa. At
subminimal inhibitory concentrations (MICs), antibiotics stimu-
late biofilm formation in P. aeruginosa and E. coli, a process that is
dependent on increasing c-di-GMP concentration (33–35). As
shown in SI Appendix, Fig. S4A, expression of H6-MBP–CSP2
reduced biofilm levels both in the absence and in the presence of
sub-MICs of tobramycin, but failed to “enhance” the bactericidal
effects of tobramycin (SI Appendix, Fig. S4B).
Altogether, these experiments indicated that CSP expression
effectively reduced biofilm formation through the specific bind-
ing and sequestration of intracellular c-di-GMP in P. aeruginosa.
To corroborate these findings and to demonstrate that the
available intracellular pool of c-di-GMP is indeed reduced, we
A
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Fig. 2. Structure of CSP1·c-di-GMP, backbone dynamics, and point mutations. (A) CleD domain structure and CSP1 amino acid sequence. The N-terminal
receiver domain (Rec) of CleD is indicated in green, the arginine-rich region CSP1 in blue, and the C-terminal region (CTR) in gray. Three arginines and two
aspartic acids involved in H bonds with c-di-GMP are highlighted in yellow. (B) Sequence alignment of the CSP region of the CleA to D paralogs. The
WebLogo3 (55) representation of this alignment (Bottom) emphasizes the conserved amino acids. The residue numbers stand for CleD. (C) Superposition of
the 10 lowest-energy structures of the CSP1·c-di-GMP complex as the best fit of residues which do not exhibit large-amplitude internal motions on the
nanosecond timescale: residues D154 to R157 and R167 to D172. (D) Lowest-energy NMR structure of intercalated dimeric c-di-GMP bound to CSP1 in ribbon
representation. The orientation is similar to C. One c-di-GMP monomer is depicted in yellow, and the other in salmon stick representation. The side chains of
W144, V145, Y150, D154, R155, R156, R157, Y163, R167, K168, R169, K170, and D172 are shown in light blue. Hydrogen bonds are depicted as dashed lines. (E)
Backbone dynamics of holo CSP1 as derived from 15N T2, T1, and {
1H}-15N NOE relaxation data (SI Appendix, Fig. S2). Exchange contributions Rex (red) from
flexibility in the micro- to millisecond range and subnanosecond order parameters S2 (blue) were calculated using the Lipari–Szabo model-free approach (56)
with an axially symmetric diffusion model (D||/⊥ = 1.95) and overall correlation time τc = 3.8 ns. The secondary structure is depicted (Top). Residues D154, R155,
R156, R169, and D172 that are involved in H bonds to the ligand are highlighted in yellow. (F) Influence of single-point mutations on c-di-GMP binding
affinity. An alanine scan (see text) of the optimized peptide CSP4 was performed and the dissociation constants were determined using ITC. The asterisk
indicates no binding for CSP4-R169A. The horizontal red line shows the Kd (177 nM) of CSP4.
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made use of a fluorescence-based reporter system that specifi-
cally responds to intracellular c-di-GMP levels (36) (Fig. 5A). To
generate the reporter, the c-di-GMP–responsive promoter of the
cdrA gene was fused transcriptionally to the gene encoding green
fluorescent protein (GFP). In the absence of c-di-GMP, the
transcriptional regulator FleQ represses cdrA transcription. In
the presence of c-di-GMP, the second messenger binds to FleQ
and induces the release of FleQ from the cdrA promoter (37)
(Fig. 5A). This results in a fluorescent readout of the cellular
c-di-GMP levels in P. aeruginosa. As a positive control for the
effect of decreasing c-di-GMP levels for cdrA promoter activity,
we used sodium nitroprusside (SNP), a compound that releases
nitric oxide, which in turn leads to the activation of the phos-
phodiesterase NbdA (38) that degrades c-di-GMP. While the
expression of H6-MBP–CSP2 effectively suppressed the synthesis
of fluorescent reporter, expression of H6-MBP–CSP2-R169A
had no effect on the c-di-GMP–dependent promoter activity
(Fig. 5B). These data strengthen the above findings that CSP
interferes with the c-di-GMP signaling network in P. aeruginosa
by directly sequestering c-di-GMP.
Discussion
Binding of c-di-GMP to proteins can be very diverse, with the
nucleotide binding as a monomer, dimer, or even tetramer in
different conformations (25, 39). Similar to all published struc-
tures with an intercalated dimeric c-di-GMP, the latter is stabi-
lized in the CSP1 complex by four intermolecular H bonds
between atoms H1 and H21 of the Watson–Crick edge of one
molecule and the O1P atom of the other (Fig. 2D).
Within the five known PilZ domain structures, six GGDEF
domain structures, and four other motifs which bind dimeric
c-di-GMP (Fig. 3 and SI Appendix, Table S5), H bond and
cation–π interactions with the ligand are formed by arginines and
aspartates distributed over several separate ligand-binding re-
gions. In contrast, in CSP1, the ligand binding is confined to a
short consecutive stretch of amino acids where three arginines
interact laterally with the Hoogsteen edges of Gua1, Gua2, and
Gua3, while D154 and D172 form H bonds with Gua1 and Gua4,
respectively. Thus, CSP1 binds c-di-GMP specifically and with
high affinity via a DRR-x11-(R/K)RxxD motif. Notably, apo
CSP1 is largely unstructured, with a 30% β-sheet propensity for
the residues that form the β-hairpin in the complexed structure.
Upon binding of c-di-GMP, apo CSP1 undergoes a classical
binding and folding transition (40). Further dynamic and
structure–activity studies identified a 19-amino acid-long peptide
with improved affinity. Currently, no other highly specific, small-
molecular mass binder to c-di-GMP exists and this peptide se-
quence may have technical applications such as sensor devel-
opment and affinity chromatography.
Based on these findings, we have developed an approach to
inhibit biofilms by directly sequestering c-di-GMP using a pep-
tide with high binding affinity in a proof-of-principle study. The
approach overcomes the redundancy of c-di-GMP turnover en-
zymes by directly targeting the common product (c-di-GMP) of
these enzymes, resulting in a more effective and universal control
of bacterial biofilms. An effective method for the disintegration
of biofilms would be an important step in the development of
new antibacterial strategies and to address the worldwide threat
of antibiotic resistance.
Our study provides the foundation for the development of a
peptide-based antibiofilm agent. However, we anticipate several
major challenges ahead with regard to the diffusion of the pep-
tide through existing biofilms, its uptake by bacterial cells, and its
stability outside and inside bacterial cells. Several strategies have
been reported that may overcome these hurdles. For example,
peptides can be combined with biofilm-“disrupting” molecules
such as EDTA (ethylenediaminetetraacetate) or DNase, which
have been shown to largely enhance the efficacies of antimi-
crobials (41, 42). To facilitate bacterial uptake, peptides can be
fused to cell-penetrating peptides (43). Finally, chemical modi-
fications can prevent proteolytic degradation and improve the
in vivo half-life of peptide drugs (44).
The peptide-sequestering approach may not be limited to
targeting the intercalated c-di-GMP dimer. A number of struc-
tures exist in the Protein Data Bank of protein complexes with
other CDNs such as c-di-AMP and the mixed-linkage cGMP-
AMP (2′3′-cGAMP). The latter plays a central role in human
and mouse cGAS/STING pathways, which are involved in the
immune response to viral infection and tumorigenesis as well as
in autoimmune diseases (45). High-affinity peptides that, for
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Fig. 3. Comparison of binding motifs of intercalated dimeric c-di-GMP. (A) The CSP1 peptide coordinates the intercalated dimeric c-di-GMP by a hitherto
unknown motif. With very few exceptions (listed in SI Appendix, Table S5), all other known motifs for binding intercalated c-di-GMP dimers either follow the
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example, target 2′3′-cGAMP could reduce inflammation in au-
toimmune diseases. While specific recognition of 2′3′-cGAMP
and other CDNs in the complex structures solved so far occurs
similarly to most c-di-GMP complexes via discontinuous ligand-
binding regions, their combination into shorter peptides may be
possible by peptide engineering or directed evolution methods.
In summary, the development of a short peptide that binds
c-di-GMP with high affinity and specificity provides opportuni-
ties for biotechnological and biomedical applications. The spe-
cific c-di-GMP sequestration presents an alternative strategy to
current drug discovery and development practices by targeting a
signaling molecule that plays a key role in the formation of
biofilms and bacterial persistence. Although many obstacles are
anticipated and remain to be solved before such an active
compound can be developed, the ability to “directly” interfere
with a central signaling pathway makes this a promising ap-
proach that deserves further exploration.
Materials and Methods
Strains, Plasmids, and Growth Conditions. The bacterial strains, plasmids, and
oligonucleotides used in this study are listed in SI Appendix, Tables S1–S3,
respectively. P. aeruginosa and E. coli were grown in lysogeny broth (LB) at
37 °C containing the appropriate selective antibiotic when required.
To construct the plasmid pET28a-H6-SUMO-CSP2 for CSP2 peptide pro-
duction, the mutagenesis to introduce K168R was performed on the plasmid
pET28a-H6-SUMO-CSP1 (for this plasmid construction, see ref. 21) using
primers prCSH1 and prCSH2. The plasmid pME6032-H6-SUMO-CSP2 (pTP16)
was constructed by inserting the NcoI- and XhoI-restricted DNA fragment of
H6-SUMO-CSP2 from pET28a-H6-SUMO-CSP2 into the same restriction sites
of the pME6032 plasmid. A restriction-free cloning method (46) was used to
generate the plasmid pME6032-CSP4 (pTP1). Primers prTP1 and prTP2 were
used to prepare CSP4 megaprimers, which were then used to introduce the
CSP4 sequence into the pME6032 plasmid. The plasmid pME6032-CSP2
(pTP33) was constructed by inserting the amplified DNA fragment of CSP2
into the EcoRI and SacI restriction sites of pME6032. Primers prTP56 and
prTP57 were used to generate the CSP2 fragment.
The plasmid pME6032-H6-MBP-CSP2-0 (pTP18) was constructed using a
restriction-free cloning method. First, megaprimers containing the MBP se-
quence were prepared from the plasmid pETG41A-H6-MBP with the primers
prTP28 and prTP29. In the secondary PCR, the megaprimers were used to
replace SUMOwith MBP in the plasmid pME6032-H6-SUMO-CSP2 that yielded the
plasmid pME6032-H6-MBP-CSP2. The same procedure was carried out to generate
pME6032-H6-TRX-CSP2-0 (pTP19) and pME6032-H6-DsbA-CSP2-0 (pTP20) by using
the primer pairs prTP31–prTP32 and prTP35–prTP36 and the plasmids pETG20A-
TRX-H6 and pETG52A-llDsbA-H6, respectively. The three constructs had low
levels of expression and, to enhance the expression, the distance of the ribo-
somal binding site to the start codon ATG of the three constructs was
optimized. The primer pair prTP49–prTP50 was used to produce pME6032-
H6-MBP-CSP2 (pTP23) and prTP50–prTP51 for both pME6032-H6-TRX-CSP2
A
B C
D E
Fig. 4. Expression of CSP fusion protein inhibits P. aeruginosa biofilm formation. (A) H6-MBP–CSP2 and H6-MBP–CSP2-R169A fusion constructs used in this
study. CSP amino acid sequences are represented in one-letter code with residue numbers according to the numbering of CleD. Bold letters highlight the
R169A mutation that prevents c-di-GMP binding. (B) Expression of H6-MBP–CSP2 inhibits biofilm formation on glass tubes while expression of the mutant
construct has no effect. The biofilm rings formed at the liquid–air interfaces were stained with crystal violet. (B, Bottom) Protein expression levels were
verified by Western blot using an anti-hexahistidine antibody. (C) H6-MBP–CSP2 expression-dependent biofilm reduction is tunable. IPTG titration leads to a
dose-dependent biofilm reduction through H6-MBP–CSP2 expression whereas no obvious effect of the mutant construct is observed. The biomass upon H6-
MBP–CSP2 expression is significantly less than that of the mutant at a concentration of 1 mM IPTG; ****P < 0.0001 (t test). Error bars represent the SD of four
different experiments. (D) Biofilm formation upon induction of expression with 1 mM IPTG over the course of 24 h. The biomass of H6-MBP–CSP2 is sig-
nificantly less than that of the mutant after 24 h of induction; ****P < 0.0001 (t test). Data are shown as means ± SD (n = 2). (E) Eradication of preformed
biofilms upon H6-MBP–CSP2 expression. Biofilms were allowed to grow for 8 h before induction with 1 mM IPTG for 16 h. The biomass of H6-MBP–CSP2 is
significantly less than that of the mutant after 16 h of induction; ****P < 0.0001 (t test). Data are shown as means ± SD (n = 2).
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(pTP22) and pME6032-H6-DsbA-CSP2 (pTP24). The R169A mutation was
introduced by site-directed mutagenesis using the primers prTP54 and
prTP55 that carry the R169A mutation. This resulted in three plasmids that
contain the mutations: pME6032-H6-DsbA-CSP2-R169A (pTP24), pME6032-
H6-MBP-CSP2-R169A (pTP31), and pME6032-H6-TRX-CSP2-R169A (pTP32).
All constructs were transformed into E. coli DH5α for storage and plasmid
preparation. All constructs were verified by DNA sequencing before trans-
formation into E. coli Rosetta for peptide production or P. aeruginosa
PAO1 (UJP505).
Protein and Peptide Expression and Purification. The peptides CSP1 and CSP2
as well as H6-CleD were produced using the following protocol. Briefly, the
plasmids (see SI Appendix, Table S2 for details) were transformed into
Rosetta (DE3) cells. Protein expression was induced with 0.5 mM IPTG at an
OD600 of 0.5 for 4 h at 37 °C. Cells from a 2-L culture were collected by
centrifugation at 4,500 × g for 15 min and then frozen at −20 °C. Pellets
were thawed and dissolved in 10 mL binding buffer (50 mM Tris·HCl, pH 8,
500 mM NaCl, 5 mM MgCl2, 30 mM imidazole), followed by sonication at
40% output power for 3 min with a repeated interval of a 1-s pulse and a 2-s
pause. Lysed cells were centrifuged at 164,700 × g for 30 min. The cell lysate
was loaded onto a 1-mL HisTrap column (GE Healthcare). The column was
then washed and the bound samples were eluted with elution buffer
(50 mM Tris·HCl, pH 8, 500 mM NaCl, 5 mM MgCl2, 500 mM imidazole) in an
eight-column volume gradient. Elution fractions were assessed by SDS-PAGE
(sodium dodecyl sulfate-polyacrylamide gel electrophoresis) to detect
expressed protein fractions. Fractions containing expressed proteins were
pooled and concentrated using a protein concentrator with a molecular
mass cutoff of 10 kDa (Millipore). Samples were loaded onto a Superdex S75
10/30 column (GE Healthcare) preequilibrated with gel-filtration buffer
(50 mM Tris·HCl, pH 8, 100 mM NaCl, 5 mM MgCl2) and the protein fractions
were assessed by SDS-PAGE.
To remove the peptides CSP1 and CSP2 from H6-SUMO, SUMO protease
ULP1 was added to purified H6-SUMO-CSP1 and H6-SUMO-CSP2 at a ratio of
5 μg to 1 mg fusion protein. The mixture was incubated at 25 °C for 16 h. The
digested sample was loaded onto a preequilibrated 1-mL HisTrap column to
remove H6-SUMO. The flowthrough containing the peptides was collected
and assessed by SDS-PAGE. Fractions containing CSP peptides were pooled,
concentrated to 1 mL, and loaded onto a Superdex S75 10/30 column pre-
equilibrated with gel-filtration buffer. Eluted fractions were assessed by
SDS-PAGE.
To prepare the isotope-labeled samples for NMR analyses, the pET28a-
H6-SUMO-CSP1 construct was transformed into Rosetta (DE3) cells and
expressed by growing the cells in 3 L of minimal medium containing 1.5 g of
15NH4Cl and 4.8 g of unlabeled or
13C-labeled glucose as sole nitrogen and
carbon sources, respectively. Peptide cleavage and purification protocols
were as described above.
Peptide Synthesis. Lyophilized peptides with at least 95% purity, except for
FITC (fluorescein isothiocyanate)-labeled peptides with at least 70% purity,
were purchased from ProteoGenix or GenScript. Peptides were dissolved in
ultrapure water and the concentrations were determined using a NanoDrop
spectrophotometer (Thermo Scientific).
NMR Spectroscopy, Resonance Assignments, and Structure Calculations. Uni-
formly 13C-15N– and 15N-labeled samples of CSP1 (0.9 to 1.0 mM) were pre-
pared in 100 mM NaCl, 20 mM phosphate, 2 mM MgCl2, 0.01% NaN3 (wt/vol;
weight/volume), 5% (vol/vol) D2O (pH 6.5) as sample volumes of 270 μL. For
complex formation, 10 mM c-di-GMP (BioLog) was titrated to the apo CSP1
sample and the fraction of apo and ligand-bound protein was monitored by
1H-15N HSQC spectra. The titration was stopped at a molar ratio of 3:1 (c-di-
GMP:CSP1), at which binding had reached saturation. Nonisotropic samples
of complexed protein were prepared by adding 17 mg/mL filamentous
phage Pf1 (Asia Biotech). Unlabeled full-length CleD samples (500 μM) with
(molar ratio 3:1) or without c-di-GMP were prepared in 200 mM NaCl, 20 mM
phosphate, 1 mM MgCl2, 0.01% NaN3 (wt/vol), 5% (vol/vol) D2O (pH 7.0) as
sample volumes of 270 μL.
All NMR spectra were recorded at 298 K on Bruker DRX 600 and DRX 900
NMR spectrometers equipped with TXI and TCI probe heads, respectively. For
resonance assignment and structure and dynamical information, standard 2D
and 3D NMR assignment, NOE, residual dipolar coupling, and relaxation
experiments were acquired similar to the ones described (47). NMR data were
processed using the NMRPipe suite of programs (48). Spectra were displayed
and analyzed with the programs SPARKY (49) and PIPP (50). Structure cal-
culations were performed with the program Xplor-NIH (51) using a simu-
lated annealing protocol (52) with the c-di-GMP molecules defined as two-
residue, circular strands of RNA. A total of 200 structures were calculated
and the 10 lowest-energy structures were selected for deposition in the
Protein Data Bank (PDB ID code 6SFT). The structural statistics are given in SI
Appendix, Table S4.
Biofilm Assay. The protocol of a standard biofilm assay was followed with
minor modifications (53). Briefly, P. aeruginosa biofilms were grown at 37 °C
without agitation in LB in 96-well plates (Falcon; 353072). After 24 h, the
optical density (OD) was measured at 600 nm in a microtiter plate reader
(EL800; BioTek) to determine bacterial growth. The plates were sub-
sequently rinsed three times with demineralized water to remove non-
attached bacteria. The adherent biofilms were stained with 0.1% crystal
violet and dissolved in 20% acetic acid, allowing quantification by measuring
the OD600 in the microtiter plate reader.
Isothermal Titration Calorimetry. ITC experiments were performed on a VP-ITC
or ITC200 microcalorimeter (MicroCal). Proteins, peptide, c-di-GMP, and
buffer (50 mM Tris·HCl, pH 8.0, 100 mM NaCl) were degassed for 15 min
prior to filling into the sample cell and syringe. All measurements were
performed at 15 °C. For measurements performed on a VP-ITC, the sample
cell contained about 10 μM protein or peptide and the syringe contained
about 200 μM c-di-GMP, with 30 injections (10 μL each) and a 250-s interval.
For ITC200, the sample cell contained about 20 μM c-di-GMP and the syringe
contained about 100 μM protein or peptide, with 18 injections (2 μL each)
and a 120-s interval. The concentrations were determined on a spectropho-
tometer using a cuvette with a 1-cm path length. The data were analyzed
using ITC Data Analysis in ORIGIN (MicroCal) provided by the manufacturer.
Microscale Thermophoresis. The binding of c-di-GMP and related nucleotides
to N-terminally FITC-labeled CSP4 (FITC-CSP4-NH2) was determined on a
Monolith NT.115 instrument with standard-treated capillaries (NanoTemper
Technologies). Fluorescence changes were recorded using blue channel op-
tics of the instrument for a 30-s period of infrared laser heating at 50% of
maximum laser power followed by a cooling period of 5 s. The measurement
B
A
Fig. 5. Expression of H6-MBP–CSP2 suppressed fluorescent signal increment
in a c-di-GMP reporter system. (A) Schematic concept showing that CSP se-
questers c-di-GMP away from the repressor FleQ in the reporter system,
resulting in suppression of GFP fluorescent signals. (B) The fluorescent signals
are shown as a ratio between treatment (IPTG or SNP) and no treatment. An
unchanged ratio as shown for H6-MBP–CSP2-R169A (IPTG/no IPTG) indicates
that IPTG induction did not suppress the increment of fluorescent signal. On
the other hand, IPTG-induced H6-MBP–CSP2 significantly suppressed the
fluorescence, indicating that the CSP2 fusions effectively sequestered c-di-
GMP away from the transcription regulator FleQ. SNP treatment in both
strains suppressed fluorescence increment. RFU, relative fluorescence unit.
The difference between H6-MBP–CSP2 and H6-MBP–CSP2-R169A signals at
12 h is statistically significant; ****P < 0.0001 (t test). Data are shown as
means ± SD (n = 3).
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buffer consisted of 50 mM Tris·HCl (pH 8.0), 100 mM NaCl, and 0.1%
polysorbate 20.
Fluorescent C-di-GMP Reporter. A fluorescent c-di-GMP reporter system was
used as previously described (36) and modified (54). The reporter consisted
of the c-di-GMP–responsive cdrA promoter transcriptionally fused to genes
encoding GFP. P. aeruginosa PAO1 strains containing the CSP expression
vectors (pTP23 and pTP31) were transformed with the pCdrA::gfp pUCP22-
NotI–based c-di-GMP–level reporter plasmid (54). The bacteria containing
both plasmids were grown overnight in LB containing the appropriate
antibiotics. The overnight cultures were diluted 1:50 in LB and grown at
37 °C on a shaker (170 rpm) until an OD600 of 0.3 was reached. Bacteria
were transferred to 96-well clear-bottom black-side plates (Costar) where
IPTG or SNP (Sigma) was added. Fluorescence (GFP: 485 nm/515 nm) and
OD600 were recorded every 30 min for 24 h using a Synergy H4 plate
reader (BioTek).
SDS-PAGE and Immunoblotting. Bacteria were grown in LB in the presence of
1 mM IPTG to induce expression of the proteins. Afterward, the cells were
diluted to an OD600 of 1. Cells were lysed by addition of SDS sample buffer
and boiled for 5 min at 99 °C. The samples were subjected to SDS-
polyacrylamide gels (Bio-Rad) and electroblotted onto nitrocellulose
membranes with a Trans-Blot SD Semi-Dry Transfer Cell (Bio-Rad). Mem-
branes were blocked for 1 h with 5% milk, 0.1% Tween 20 PBS
(phosphate-buffered saline) at room temperature followed by primary
antibody application at 4 °C with a mouse anti-His antibody (GE Healthcare)
diluted in 5% milk, 0.1% Tween 20 PBS. Horseradish peroxidase-conjugated
secondary antibodies were purchased from Cell Signaling Technology. The
blots were developed with an enhanced chemiluminescence reagent (LumiGlo
Reserve; KPL) and imaged using an ImageQuant LAS-4000 System (Fujitsu
Life Sciences).
Data Availability. The assignments and details of the acquired NMR spectra
have been deposited in the Biological Magnetic Resonance Data Bank (BMRB
ID codes 27990 [apo CSP1] and 50001 [CSP1·c-di-GMP]). The 10 lowest-energy
structures of the CSP1·c-di-GMP complex have been deposited in the Protein
Data Bank (PDB ID code 6SFT).
ACKNOWLEDGMENTS. We gratefully acknowledge Dr. Timothy Sharpe of
the Biozentrum Biophysics Facility for expert help with the biophysical
characterization of CSP. This work was supported by the Swiss Commission
for Technology and Innovation (Grant 18366.1 PFLS-LS to C.-S.H., C.S., U.J.,
and T.S.) and Swiss National Science Foundation (Grants 31-149927 and 31-
173089 to S.G., Grant 31-166652 to T.S., and Grant 31-147090 to U.J.).
1. K. A. McDonough, A. Rodriguez, The myriad roles of cyclic AMP in microbial patho-
gens: From signal to sword. Nat. Rev. Microbiol. 10, 27–38 (2011).
2. Z. D. Dalebroux, M. S. Swanson, ppGpp: Magic beyond RNA polymerase. Nat. Rev.
Microbiol. 10, 203–212 (2012).
3. U. Jenal, A. Reinders, C. Lori, Cyclic di-GMP: Second messenger extraordinaire. Nat.
Rev. Microbiol. 15, 271–284 (2017).
4. B. W. Davies, R. W. Bogard, T. S. Young, J. J. Mekalanos, Coordinated regulation of
accessory genetic elements produces cyclic di-nucleotides for V. cholerae virulence.
Cell 149, 358–370 (2012).
5. D. Cohen et al., Cyclic GMP-AMP signalling protects bacteria against viral infection.
Nature 574, 691–695 (2019).
6. J. Gundlach et al., Control of potassium homeostasis is an essential function of
the second messenger cyclic di-AMP in Bacillus subtilis. Sci. Signal. 10, eaal3011
(2017).
7. C. L. Hall, V. T. Lee, Cyclic-di-GMP regulation of virulence in bacterial pathogens.
Wiley Interdiscip. Rev. RNA 9, e1454 (2018).
8. U. Römling, M. Y. Galperin, M. Gomelsky, Cyclic di-GMP: The first 25 years of a
universal bacterial second messenger. Microbiol. Mol. Biol. Rev. 77, 1–52
(2013).
9. U. Römling, C. Balsalobre, Biofilm infections, their resilience to therapy and in-
novative treatment strategies. J. Intern. Med. 272, 541–561 (2012).
10. P. Gupta, S. Sarkar, B. Das, S. Bhattacharjee, P. Tribedi, Biofilm, pathogenesis and
prevention—A journey to break the wall: A review. Arch. Microbiol. 198, 1–15
(2016).
11. T. Bjarnsholt, O. Ciofu, S. Molin, M. Givskov, N. Høiby, Applying insights from biofilm
biology to drug development—Can a new approach be developed? Nat. Rev. Drug
Discov. 12, 791–808 (2013).
12. S. Wagner et al., Novel strategies for the treatment of Pseudomonas aeruginosa in-
fections. J. Med. Chem. 59, 5929–5969 (2016).
13. A. Boehm et al., Second messenger-mediated adjustment of bacterial swimming ve-
locity. Cell 141, 107–116 (2010).
14. K. S. Sprecher et al., Cohesive properties of the Caulobacter crescentus holdfast
adhesin are regulated by a novel c-di-GMP effector protein. MBio 8, e00294-17
(2017).
15. D. Pérez-Mendoza, J. Sanjuán, Exploiting the commons: Cyclic diguanylate regu-
lation of bacterial exopolysaccharide production. Curr. Opin. Microbiol. 30, 36–43
(2016).
16. L. D. Christensen et al., Clearance of Pseudomonas aeruginosa foreign-body biofilm
infections through reduction of the cyclic di-GMP level in the bacteria. Infect. Immun.
81, 2705–2713 (2013).
17. H. Kulasakara et al., Analysis of Pseudomonas aeruginosa diguanylate cyclases and
phosphodiesterases reveals a role for bis-(3′-5′)-cyclic-GMP in virulence. Proc. Natl.
Acad. Sci. U.S.A. 103, 2839–2844 (2006).
18. C. Opoku-Temeng, J. Zhou, Y. Zheng, J. Su, H. O. Sintim, Cyclic dinucleotide (c-di-GMP,
c-di-AMP, and cGAMP) signalings have come of age to be inhibited by small mole-
cules. Chem. Commun. (Camb.) 52, 9327–9342 (2016).
19. R. Hengge, Principles of c-di-GMP signalling in bacteria. Nat. Rev. Microbiol. 7,
263–273 (2009).
20. S. Nakayama, J. Zhou, Y. Zheng, H. Szmacinski, H. O. Sintim, Supramolecular polymer
formation by cyclic dinucleotides and intercalators affects dinucleotide enzymatic
processing. Future Sci. OA 2, FSO93 (2016).
21. J. Nesper et al., Cyclic di-GMP differentially tunes a bacterial flagellar motor through
a novel class of CheY-like regulators. eLife 6, e28842 (2017).
22. I. S. Pultz et al., The response threshold of Salmonella PilZ domain proteins is de-
termined by their binding affinities for c-di-GMP. Mol. Microbiol. 86, 1424–1440
(2012).
23. T. Schirmer, C-di-GMP synthesis: Structural aspects of evolution, catalysis and regu-
lation. J. Mol. Biol. 428, 3683–3701 (2016).
24. J. Habazettl, M. G. Allan, U. Jenal, S. Grzesiek, Solution structure of the PilZ domain
protein PA4608 complex with cyclic di-GMP identifies charge clustering as molecular
readout. J. Biol. Chem. 286, 14304–14314 (2011).
25. S.-H. Chou, M. Y. Galperin, Diversity of cyclic di-GMP-binding proteins and mecha-
nisms. J. Bacteriol. 198, 32–46 (2016).
26. G. Lipari, A. Szabo, Model-free approach to the interpretation of nuclear mag-
netic resonance relaxation in macromolecules. J. Am. Chem. Soc. 104, 4546–4559
(1983).
27. D. L. Burdette et al., STING is a direct innate immune sensor of cyclic di-GMP. Nature
478, 515–518 (2011).
28. O. Danilchanka, J. J. Mekalanos, Cyclic dinucleotides and the innate immune re-
sponse. Cell 154, 962–970 (2013).
29. S. Ouyang et al., Structural analysis of the STING adaptor protein reveals a hydro-
phobic dimer interface and mode of cyclic di-GMP binding. Immunity 36, 1073–1086
(2012).
30. N. Shaw, S. Ouyang, Z.-J. Liu, Binding of bacterial secondary messenger molecule c di-
GMP is a STING operation. Protein Cell 4, 117–129 (2013).
31. X. Zhang et al., Cyclic GMP-AMP containing mixed phosphodiester linkages is an
endogenous high-affinity ligand for STING. Mol. Cell 51, 226–235 (2013).
32. Y. Li, Recombinant production of antimicrobial peptides in Escherichia coli: A review.
Protein Expr. Purif. 80, 260–267 (2011).
33. J. B. Kaplan, Antibiotic-induced biofilm formation. Int. J. Artif. Organs 34, 737–751
(2011).
34. L. R. Hoffman et al., Aminoglycoside antibiotics induce bacterial biofilm formation.
Nature 436, 1171–1175 (2005).
35. A. Boehm et al., Second messenger signalling governs Escherichia coli biofilm in-
duction upon ribosomal stress. Mol. Microbiol. 72, 1500–1516 (2009).
36. M. T. Rybtke et al., Fluorescence-based reporter for gauging cyclic di-GMP
levels in Pseudomonas aeruginosa. Appl. Environ. Microbiol. 78, 5060–5069
(2012).
37. J. W. Hickman, C. S. Harwood, Identification of FleQ from Pseudomonas aerugi-
nosa as a c-di-GMP-responsive transcription factor. Mol. Microbiol. 69, 376–389
(2008).
38. Y. Li, S. Heine, M. Entian, K. Sauer, N. Frankenberg-Dinkel, NO-induced biofilm dis-
persion in Pseudomonas aeruginosa is mediated by an MHYT domain-coupled
phosphodiesterase. J. Bacteriol. 195, 3531–3542 (2013).
39. T. Schirmer, U. Jenal, Structural and mechanistic determinants of c-di-GMP signalling.
Nat. Rev. Microbiol. 7, 724–735 (2009).
40. K. Sugase, H. J. Dyson, P. E. Wright, Mechanism of coupled folding and binding of an
intrinsically disordered protein. Nature 447, 1021–1025 (2007).
41. Z. Liu et al., In vitro and in vivo activity of EDTA and antibacterial agents
against the biofilm of mucoid Pseudomonas aeruginosa. Infection 45, 23–31
(2017).
42. R. Cavaliere, J. L. Ball, L. Turnbull, C. B. Whitchurch, The biofilm matrix destabilizers,
EDTA and DNaseI, enhance the susceptibility of nontypeable Hemophilus influenzae
biofilms to treatment with ampicillin and ciprofloxacin.MicrobiologyOpen 3, 557–567
(2014).
43. K. A. Brogden, Antimicrobial peptides: Pore formers or metabolic inhibitors in bac-
teria? Nat. Rev. Microbiol. 3, 238–250 (2005).
44. K. Fosgerau, T. Hoffmann, Peptide therapeutics: Current status and future directions.
Drug Discov. Today 20, 122–128 (2015).
45. J. Tao, X. Zhou, Z. Jiang, cGAS-cGAMP-STING: The three musketeers of cytosolic DNA
sensing and signaling. IUBMB Life 68, 858–870 (2016).
46. S. R. Bond, C. C. Naus, RF-cloning.org: An online tool for the design of restriction-free
cloning projects. Nucleic Acids Res. 40, W209–W213 (2012).
47. S. Grzesiek et al., Refined solution structure and backbone dynamics of HIV-1 Nef.
Protein Sci. 6, 1248–1263 (1997).
Hee et al. PNAS | July 21, 2020 | vol. 117 | no. 29 | 17219
M
IC
RO
BI
O
LO
G
Y
48. F. Delaglio et al., NMRPipe: A multidimensional spectral processing system based on
UNIX pipes. J. Biomol. NMR 6, 277–293 (1995).
49. T. D. Goddard, D. G. Kneller, SPARKY 3 (University of California, San Francisco, CA,
2008).
50. D. Garrett, R. Powers, A. Gronenborn, G. Clore, A common sense approach to peak
picking in two-, three-, and four dimensional spectra using automatic computer
analysis of contour diagrams. J. Magn. Reson. 95, 214–220 (1991).
51. C. D. Schwieters, J. J. Kuszewski, N. Tjandra, G. M. Clore, The Xplor-NIH NMR mo-
lecular structure determination package. J. Magn. Reson. 160, 65–73 (2003).
52. M. Nilges, G. M. Clore, A. M. Gronenborn, Determination of three-dimensional
structures of proteins from interproton distance data by hybrid distance geometry-
dynamical simulated annealing calculations. FEBS Lett. 229, 317–324 (1988).
53. G. A. O’Toole et al., Genetic approaches to study of biofilms. Methods Enzymol. 310,
91–109 (1999).
54. U. N. Broder, T. Jaeger, U. Jenal, LadS is a calcium-responsive kinase that induces
acute-to-chronic virulence switch in Pseudomonas aeruginosa. Nat. Microbiol. 2,
16184 (2016).
55. G. E. Crooks, G. Hon, J. M. Chandonia, S. E. Brenner, WebLogo: A sequence logo
generator. Genome Res. 14, 1188–1190 (2004).
56. G. Lipari, A. Szabo, Model-free approach to the interpretation of nuclear magnetic
resonance relaxation in macromolecules. 2. Analysis of experimental results. J. Am.
Chem. Soc. 104, 4559–4570 (1982).
57. C. Chan et al., Structural basis of activity and allosteric control of diguanylate cyclase.
Proc. Natl. Acad. Sci. U.S.A. 101, 17084–17089 (2004).
17220 | www.pnas.org/cgi/doi/10.1073/pnas.2001232117 Hee et al.
